CAU
BIO icon

Caxton Associates (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Caxton Associates (UK)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07M Buy
+13,875
New +$3.94M 0.08% 106
2026
Q1 		– Sell
-1,467
Closed -$444K – 790
2025
Q4 		$444K Buy
+1,467
New +$458K 0.01% 530
2025
Q2 		– Sell
-2,998
Closed -$730K – 702
2025
Q1 		$730K Buy
+2,998
New +$902K 0.03% 388

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Caxton Associates (UK)'s BIO Position: Q2 2026 in Review

Caxton Associates (UK) opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 13,875 shares worth $4.07M. The stake represents 0.08% of the portfolio and ranks #106 among its holdings. This is a return to the name: Caxton Associates (UK) previously reported a position in BIO as recently as Q4 2025.

Caxton Associates (UK) first reported a position in BIO in Q1 2025 and has held it in 3 quarters since. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Caxton Associates (UK) held 13,875 shares of Bio-Rad Laboratories Class A worth $4.07M as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Caxton Associates (UK) position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.08% of Caxton Associates (UK)'s portfolio in Q2 2026, its #106 holding.
  • Caxton Associates (UK) first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and has held it in 3 quarters since.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Caxton Associates (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.